CClinicalTrials.gg
Status unknownNCT04192760BBK-3Updated Aug 5, 2022

Culotte Versus DK-CRUSH Technique in Non-left Main Coronary Bifurcation Lesions

An interventional study of Stenting in Coronary Stenosis and Stent Stenosis, sponsored by University Heart Center Freiburg - Bad Krozingen. Status unknown at 13 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by University Heart Center Freiburg - Bad Krozingen · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Randomised comparison of Culotte technique versus "Double Kissing" - Crush technique (DK-Crush) for the percutaneous treatment of de novo non-left main coronary bifurcation lesions with modern everolimus-eluting stents (DES) - German multicenter study

Read the detailed description

Aim of study This prospective randomized multicenter study will compare the long-term safety and efficacy of Culotte stenting versus "Double Kissing" - Crush (DK-Crush) stenting in the treatment of the de-novo non-left main coronary bifurcation lesions with new generation everolimus-eluting stents.

Study hypothesis In large coronary bifurcation lesions (main vessel > 2.5mm, side branch > 2.25mm) including significant ostial side branch disease, Culotte stenting compared with DKcrush stenting reduces maximal percent diameter stenosis at the bifurcation at 9-month follow-up by 25 %.

Study design Prospective, randomized, German multicenter study.

Methods Four-hundred patients, in whom a double-stenting technique is intended for the treatment of a non-left main de-novo coronary bifurcation lesion will be randomly assigned to Culotte stenting or to DK-crush stenting with an approved drug-eluting stent (SYNERGY-Stent). As a part of usual care, patients will undergo 9-month angiographic follow-up with quantitative coronary angiography. Clinical follow-up is planned at 1 year if no angiographic follow-up is obtained.

02

Conditions studied

  • Coronary Stenosis
  • Stent Stenosis

Keywords

  • PCI
  • stent
  • bifurcation
  • Culotte
  • DK-Crush
  • restenosis
03

In context

Coronary Stenosis

302 studies on the registry are indexed under Coronary Stenosis; 63 are open to participants now.

This study's planned enrollment of 400 is above the median of 200 across 160 interventional studies indexed under Coronary Stenosis.

Browse Coronary Stenosis studies →

Lead sponsor

University Heart Center Freiburg - Bad Krozingen is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Clinical indication, evidenced by angina / angina-equivalent symptoms or documented ischemia (non-invasive imaging such as scintigraphy, stress-MRI or stress-echo; FFR or iwFR) or patients with acute coronary syndromes (NSTE-ACS).
  2. Clinical indication to perform double stenting only with Synergy™ stents for a clinically significant bifurcation stenosis as judged by the operator.
  3. De-novo non-Ieft main coronary bifurcation lesions - 1,1,1 or 0,1,1 according to the Medina classification - of a native coronary artery with the following reference vessel diameters: main branch > 2,5 mm; side branch > 2,25 mm. The difference between vessel diameter of the main and side branch is ≤ 1 mm.
  4. The target lesion has not been previously treated with any interventional procedure.
  5. The target vessel (main branch and side branch) must appear feasible for stent implantation.
  6. Patient has no other coronary intervention planned within 30 days of the procedure.
  7. Patient has been informed of the nature of the study and agrees to its provisions and has written informed consent as approved by the Ethics Committee.
  8. Patient is willing to comply with all required post-procedure follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patient had an acute ST-elevation myocardial infarction within 72 h preceding the index procedure or target vessel contains intraluminal thrombus.
  2. Use of any other coronary stent than Synergy™ and Synergy Megatron™ except for baiI-out situations.
  3. Patient with a known hypersensitivity or contraindication to the needed antithrombotic therapy, stent type or contrast media that cannot be adequately pre-medicated.
  4. Non successful treatment of other lesion during the same procedure.
  5. Patient with a severe bleeding diathesis, history of recent major bleeding or stroke (≤ 6 months), coagulopathy or severe liver disease.
  6. Patient has a co-morbidity (i.e. cancer) that may cause the patient to be noncompliant with the protocol, or is associated with limited life-expectancy (Iess than 1 year).
  7. Patient is participating in any other clinical study with an investigational product.
  8. Patient is known to be pregnant or lactating at time of inclusion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Culotte Technique

    Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.

    Procedure: Stenting

  • Active comparator
    DK-Crush Technique

    Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed). After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment).

    Procedure: Stenting

Interventions

  • ProcedureStenting

    Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions

06

What researchers measure

Primary outcomes

  1. Angiographic restenosis in the bifurcation lesion by quantitative coronary analysis (QCA)

    For quantitative coronary angiography, changes between result at the completion of the index intervention and at 9 months follow-up will be analysed using a computer based system dedicated to bifurcation analysis, according to the standard operating procedure of the angiographic core laboratory. Quantitative angiographic measurements will be obtained of the three segments of the bifurcation lesion: the proximal and distal segment of the main branch and the side branch. We will perform measurements in the stented portion of the vessel (in-stent) and in the distal or proximal 5 mm margin (edge). In-segment analyses will comprise the in-stent and the edge area. In addition, the bifurcation angle from the analysis system will be estimated.

    Time frame: 9 months post index percutaneous coronary intervention (PCI)

Secondary outcomes

  1. Incidence of target lesion revascularisation (TLR)

    Any revascularisation (Re-PCI or CABG) at segments treated during index procedure

    Time frame: 1 year

  2. Incidence of major adverse cardiac events (MACE)

    MACE defined as death, Myocardial infarction (Q wave and Non-Q wave), emergent cardiac bypass surgery, or TLR

    Time frame: 1 year

  3. Incidence of binary restenosis at any segment of the bifurcation lesion

    ≥ 50% diameter stenosis in the main and side branch

    Time frame: 9 months

  4. Incidence of binary restenosis in the main and side branch

    ≥ 50% diameter stenosis in main and side branch

    Time frame: 9 months

  5. Incidence of stent thrombosis (ST)

    Post-procedure thrombotic stent occlusion according to the Academic Research Consortium-criteria

    Time frame: 1 year

Other outcomes

  1. Rate of device success

    Attainment of \< 30% residual stenosis of the target lesion in the main and side branch

    Time frame: 9 months

  2. Mean procedure time

    Procedure time measured in minutes

    Time frame: Index Intervention

  3. Mean radiation exposure

    Radiation exposure measured in cGym²

    Time frame: Index Intervention

  4. Mean volume of used contrast medium

    Contrast medium measured in milliliters

    Time frame: Index Intervention

07

Study locations

13 of 13 sites recruiting
  • University Heart Center Freiburg • Bad Krozingen
    Bad Krozingen, Suedring 15 79189, Germany
    Recruiting
  • Herz-u. Diabeteszentrum
    Bad Oeynhausen, 32545, Germany
    Recruiting
  • Herz-und Gefäßzentrum
    Bad Segeberg, 23795, Germany
    Recruiting
  • St. Johannes-Hospital
    Dortmund, 44137, Germany
    Recruiting
  • Herzzentrum Dresden an der Technischen Universität
    Dresden, 01307, Germany
    Recruiting
  • Elisabeth Krankenhaus
    Essen, 45138, Germany
    Recruiting
  • Universitätsklinikum Gießen
    Gießen, 35392, Germany
    Recruiting
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
    Recruiting
  • Universitätsklinik Mannheim
    Mannheim, 68167, Germany
    Recruiting
  • Deutsches Herzzentrum
    München, 80636, Germany
    Recruiting
  • Klinikum Oldenburg
    Oldenburg, 26133, Germany
    Recruiting
  • Herzzentrum Trier
    Trier, 54292, Germany
    Recruiting
  • Universitätsklinikum Ulm
    Ulm, 89070, Germany
    Recruiting
08

References and documents

Publications

  • Ferenc M, Gick M, Comberg T, Rothe J, Valina C, Toma A, Loffelhardt N, Hochholzer W, Riede F, Kienzle RP, Achtari A, Neumann FJ. Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. Eur Heart J. 2016 Dec 1;37(45):3399-3405. doi: 10.1093/eurheartj/ehw345. Epub 2016 Aug 30. PubMed 27578807 ↗
  • Chen SL, Xu B, Han YL, Sheiban I, Zhang JJ, Ye F, Kwan TW, Paiboon C, Zhou YJ, Lv SZ, Dangas GD, Xu YW, Wen SY, Hong L, Zhang RY, Wang HC, Jiang TM, Wang Y, Sansoto T, Chen F, Yuan ZY, Li WM, Leon MB. Clinical Outcome After DK Crush Versus Culotte Stenting of Distal Left Main Bifurcation Lesions: The 3-Year Follow-Up Results of the DKCRUSH-III Study. JACC Cardiovasc Interv. 2015 Aug 24;8(10):1335-1342. doi: 10.1016/j.jcin.2015.05.017. PubMed 26315736 ↗
  • Chen SL, Zhang JJ, Ye F, Chen YD, Lu SZ, Tan H, Patel T, Kenji K, Tamari I, Shan SJ, Zhu ZS, Lin S, Tian NL, Li XB, Liu ZZ, Lee M, Wei M, Xu YW, Yuan ZB, Qian J, Sun XW, Yang S, Chen JG, He B, Sumit S. [Comparison of DK crush with classical crush technique with drug-eluting stents for the treatment of coronary bifurcation lesions from DKCRUSH-1 study]. Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Feb;36(2):100-7. Chinese. PubMed 19099943 ↗
  • Chen SL, Santoso T, Zhang JJ, Ye F, Xu YW, Fu Q, Kan J, Paiboon C, Zhou Y, Ding SQ, Kwan TW. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. J Am Coll Cardiol. 2011 Feb 22;57(8):914-20. doi: 10.1016/j.jacc.2010.10.023. PubMed 21329837 ↗
  • Erglis A, Kumsars I, Niemela M, Kervinen K, Maeng M, Lassen JF, Gunnes P, Stavnes S, Jensen JS, Galloe A, Narbute I, Sondore D, Makikallio T, Ylitalo K, Christiansen EH, Ravkilde J, Steigen TK, Mannsverk J, Thayssen P, Hansen KN, Syvanne M, Helqvist S, Kjell N, Wiseth R, Aaroe J, Puhakka M, Thuesen L; Nordic PCI Study Group. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study. Circ Cardiovasc Interv. 2009 Feb;2(1):27-34. doi: 10.1161/CIRCINTERVENTIONS.108.804658. Epub 2009 Feb 10. PubMed 20031690 ↗
  • Ferenc M, Buettner HJ, Gick M, Comberg T, Rothe J, Khoury F, Valina C, Toma A, Kuebler P, Riede F, Neumann FJ. Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents. Clin Res Cardiol. 2016 Mar;105(3):230-8. doi: 10.1007/s00392-015-0911-7. Epub 2015 Sep 2. PubMed 26329585 ↗
  • Lee JM, Hahn JY, Kang J, Park KW, Chun WJ, Rha SW, Yu CW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Gwon HC, Koo BK, Kim HS. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. JACC Cardiovasc Interv. 2015 Aug 24;8(10):1318-1331. doi: 10.1016/j.jcin.2015.05.014. PubMed 26315734 ↗

Study documents

  • Study protocol · Dec 1, 2020
  • Statistical analysis plan · Dec 9, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04192760
Lead sponsor
University Heart Center Freiburg - Bad Krozingen
Responsible party
Dr. Miroslaw FERENC (Director of interventional cardiology department, University Heart Center Freiburg - Bad Krozingen) — Principal investigator
First posted
Dec 10, 2019
Start date
Dec 1, 2019
Primary completion
Mar 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Aug 5, 2022

Study contacts

Miroslaw Ferenc, MD
Contact
miroslaw.ferenc@uniklinik-freiburg.de
0049 7633 4020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion